


Searching News Database: Moberg Pharma
HSMN NewsFeed - 9 Dec 2019
Moberg Pharma Meets Primary Endpoint for MOB-015 in a Phase 3 Study for the Treatment of Onychomycosis
Moberg Pharma Meets Primary Endpoint for MOB-015 in a Phase 3 Study for the Treatment of Onychomycosis
